Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report
- Authors:
- Published online on: November 7, 2013 https://doi.org/10.3892/ol.2013.1664
- Pages: 50-52
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Hepatocellular carcinoma (HCC) is the third most common cause of cancer‑associated mortality worldwide. No effective treatment has been established for unresectable advanced HCC, and the prognosis is poor. Sorafenib is an oral multi‑targeted tyrosine kinase inhibitor for unresectable advanced HCC that significantly improves progression‑free and overall survival. However, in the two large phase III clinical trials (the SHARP and Asia‑Pacific trials), no cases of complete response (CR) were reported. The present study reports the case of a 68‑year‑old male with hepatitis C virus‑related cirrhosis and multiple recurrent HCCs, with a tumor thrombus of the third portal vein following resection. The patient received 400 mg once daily (half the standard dose) of sorafenib for two years and achieved a CR. At the most recent follow‑up examination at one year after the cessation of treatment, the patient was observed to be in remission without clinical or imaging evidence of disease recurrence.